Literature DB >> 3456246

High frequency of N-ras activation in acute myelogenous leukemia.

S W Needleman, M H Kraus, S K Srivastava, P H Levine, S A Aaronson.   

Abstract

Using the NIH/3T3 cell transfection assay, activated cellular oncogenes have been detected in around 10% to 20% of human tumors. From a series of DNA preparations from tissues infiltrated with acute myelogenous leukemia (AML), 50% (3/6) caused transformation of NIH/3T3 cells. Thus AML appears to be the human tumor with the highest frequency of oncogenes detected by DNA transfection. In each case the oncogene involved was N-ras, a member of the ras gene family. Biologic and clinical parameters of AML patients with and without N-ras oncogenes in their tumors are discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3456246

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Oncogenicity of human N-ras oncogene and proto-oncogene introduced into retroviral vectors.

Authors:  M Souyri; I Vigon; M Charon; P Tambourin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

Review 2.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.

Authors:  G D Demetri; T J Ernst; E S Pratt; B W Zenzie; J G Rheinwald; J D Griffin
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

Review 4.  Cancer genes generated by rare chromosomal rearrangements rather than activation of oncogenes.

Authors:  P H Duesberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

Review 5.  The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer.

Authors:  P J Chiao; F Z Bischoff; L C Strong; M A Tainsky
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

Review 6.  Cancer genes: rare recombinants instead of activated oncogenes (a review).

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Concurrent mutations in two different ras genes in acute myelocytic leukemias.

Authors:  J W Janssen; J Lyons; A C Steenvoorden; H Seliger; C R Bartram
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

8.  Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Authors:  Radharani Gollamudi; Mohammad H Ghalib; Kavita K Desai; Imran Chaudhary; Benny Wong; Mark Einstein; Matthew Coffey; George M Gill; Karl Mettinger; John M Mariadason; Sridhar Mani; Sanjay Goel
Journal:  Invest New Drugs       Date:  2009-07-02       Impact factor: 3.850

9.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors:  Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.